Novartis AG (NYSE:NVS) Shares Bought by Foresight Capital Management Advisors Inc.

Foresight Capital Management Advisors Inc. lifted its position in shares of Novartis AG (NYSE:NVS) by 7.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,604 shares of the company’s stock after purchasing an additional 1,729 shares during the period. Foresight Capital Management Advisors Inc.’s holdings in Novartis were worth $2,394,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Northside Capital Management LLC raised its stake in Novartis by 29.5% during the 4th quarter. Northside Capital Management LLC now owns 3,296 shares of the company’s stock valued at $321,000 after acquiring an additional 750 shares during the last quarter. Heritage Family Offices LLP raised its stake in Novartis by 1.9% during the 4th quarter. Heritage Family Offices LLP now owns 6,107 shares of the company’s stock valued at $594,000 after acquiring an additional 112 shares during the last quarter. Flywheel Private Wealth LLC purchased a new stake in Novartis during the 4th quarter valued at approximately $272,000. Godsey & Gibb Inc. raised its stake in Novartis by 0.5% during the 4th quarter. Godsey & Gibb Inc. now owns 192,287 shares of the company’s stock valued at $18,711,000 after acquiring an additional 949 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. increased its position in Novartis by 176.3% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,688 shares of the company’s stock worth $164,000 after purchasing an additional 1,077 shares during the period. Institutional investors and hedge funds own 13.12% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on NVS. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. BMO Capital Markets upped their price target on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. Finally, HSBC cut Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Two research analysts have rated the stock with a sell rating and seven have assigned a hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $121.50.

Novartis Trading Down 0.3 %

NYSE:NVS opened at $99.05 on Thursday. The business’s 50-day moving average is $101.13 and its two-hundred day moving average is $109.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The firm has a market capitalization of $202.46 billion, a PE ratio of 11.50, a price-to-earnings-growth ratio of 1.36 and a beta of 0.57.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. The company had revenue of $12.82 billion during the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a return on equity of 34.80% and a net margin of 35.96%. During the same period last year, the firm earned $1.74 earnings per share. Research analysts predict that Novartis AG will post 7.63 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.